Table 2.

Results

Results, n (%)axSpA (n=22, 61%)PsA (n=13, 39%)
Positive ADAbs8 (22) 2 (15)
Therapeutic drug levels14 (39) 6 (43)
High ADAbs and very low or undetectable drug (likely drug-neutralising) 12 (9)2 (15)
Drug discontinuation (no alternative biologic required) 21 (5)1 (5)
Change to alternative biologic (either within same class or different mode of action biologic) 30 (0)2 (6)
Switched to biosimilar12 (54) 8 (62)

  • ↵1Undetectable DL in 3 subjects.

  • ↵2Subjects in clinical remission and undetectable drug level.

  • ↵3One subject with active skin disease (PsA) and one subject with active joint disease (PsA).

    axSpA = Axial spondyloarthritis; PsA = psoriatic arthritis.